دراسة مستوى التستوستيرون االمصلي بعد تطبيق المعالجة المثبطة للأندروجين :ADH عند مرضى سرطان الموثة النقائلي (خبرة مشفى تشرين الجامعي في اللاذقية بين عامي 2013-2014)
Abstract
شملت هذه الدراسة 30 مريضا لديهم سرطان موثة نقائلي , راجعوا قسم الأورام في مشفى تشرين الجامعي في اللاذقية بين عامي 2014 -2013جميع المرضى درسوا من حيث الscore gleason(مشعر غليسون) والعمر ومشعر كتلة الجسم ((BMI. جميع المرضى تلقوا علاج بشادات LHRH(goserelin 3,6 mg) بحقن شهرية تحت الجلد مع مشاركته خلال أول أسبوعين بمثبطات الأندروجين المحيطية. تم عيار ال PSA وال Testosteron قبل بدء العلاج ثم بعد شهر واحد ثم بعد 6 أشهر من بدء العلاج ,إضافة إلى مراقبة الاّثار الجانبية للعلاج الهرموني المستخدم والنتائج بعد شهر من العلاج: عدم وجود علاقة بين مشعر كتلة الجسم والتستوستيرون. شادات LHRH تحقق نسبة استجابة تقدر ب 90 %بتخفيضها لللتستوستيرون لقيمأاقل من 50 نغ/دل و76% وصل لديهم التستوستيرون لقيم أقل من 20 نغ /دل.أهم الاّثار الجانبية : الاكتئاب 72% و الهبات الساخنة 33% والصداع 30%. In this study : 30 patients with metastatic prostate cancer who admitted to the department of Oncology, Tishreen University Hospital, Lattakia, Syria between 2013 and 2014 were grouped according to gleason score , age and body mass index. All patient received treatment with LHRH agonist (goserelin 3,6 mg subcutaneous injection monthly) combined with anti-androgen for two weeks. PSA and testosterone were measured in all patients before treatment then after 1 and after 6 month and the side effects were documented. Results post ADH treatment: There is no relationship between body mass index and testosterone level. Hormonal treatment with LHRH agonist reduced testosterone to 50 ng/dl in 90% of the patients, whereas 76%of the cases achieved testosterone levels 20ng/dl. The most common treatment-related adverse event was depression 72% , hot flash 33% and headache 30%.Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series
Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in Tishreen University Journal for Research and Scientific Studies - Health Sciences Series . The Readers have the right to send, print and subscribe to the initial version of the article, and the title of Tishreen University Journal for Research and Scientific Studies - Health Sciences Series Publisher
journal uses a CC BY-NC-SA license which mean
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.